bispecific antibodies
| 4 min read
Cancer researchers in biotech and pharma highlight the clinical trials and developments they’re most excited about.
| 1 min read
ProBioGen announced the commercial launch of Ziihera®, a bispecific antibody for HER2-positive biliary tract cancer developed with its GlymaxX® technology.
Available on Demand
Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.
Page 1 of 1 - 3 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
